The stock of Ignyta Inc (NASDAQ:RXDX) is a huge mover today! About 92,909 shares traded hands. Ignyta Inc (NASDAQ:RXDX) has declined 11.38% since March 8, 2016 and is downtrending. It has underperformed by 20.70% the S&P500.
The move comes after 9 months negative chart setup for the $243.25 million company. It was reported on Oct, 11 by Barchart.com. We have $5.08 PT which if reached, will make NASDAQ:RXDX worth $31.62 million less.
Analysts await Ignyta Inc (NASDAQ:RXDX) to report earnings on November, 14. They expect $-0.66 earnings per share, down 34.69% or $0.17 from last year’s $-0.49 per share. After $-0.68 actual earnings per share reported by Ignyta Inc for the previous quarter, Wall Street now forecasts -2.94% EPS growth.
Ignyta Inc (NASDAQ:RXDX) Ratings Coverage
Out of 6 analysts covering Ignyta (NASDAQ:RXDX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ignyta has been the topic of 10 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The stock of Ignyta Inc (NASDAQ:RXDX) has “Buy” rating given on Monday, October 26 by Canaccord Genuity. The rating was initiated by JP Morgan with “Overweight” on Thursday, June 23. The stock has “Outperform” rating given by Credit Suisse on Tuesday, March 15. The stock has “Outperform” rating given by Credit Suisse on Thursday, January 21. On Tuesday, November 10 the stock rating was initiated by Cantor Fitzgerald with “Buy”. The stock has “Overweight” rating given by Piper Jaffray on Wednesday, August 12. Jefferies initiated Ignyta Inc (NASDAQ:RXDX) rating on Friday, October 23. Jefferies has “Buy” rating and $18 price target. The rating was initiated by Cantor Fitzgerald on Monday, October 26 with “Buy”.
According to Zacks Investment Research, “Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California.”
Insitutional Activity: The institutional sentiment increased to 2.87 in Q2 2016. Its up 1.47, from 1.4 in 2016Q1. The ratio improved, as 6 funds sold all Ignyta Inc shares owned while 9 reduced positions. 11 funds bought stakes while 32 increased positions. They now own 24.37 million shares or 38.14% more from 17.64 million shares in 2016Q1.
Deutsche Natl Bank Ag reported 11,305 shares or 0% of all its holdings. Tfs Cap Ltd Liability Corp accumulated 65,576 shares or 0.07% of the stock. Nationwide Fund Advsr holds 0% of its portfolio in Ignyta Inc (NASDAQ:RXDX) for 32,394 shares. Rhumbline Advisers accumulated 0% or 27,635 shares. Legal General Grp Inc Public has invested 0% of its portfolio in Ignyta Inc (NASDAQ:RXDX). Ubs Oconnor Ltd Co accumulated 0% or 34,056 shares. Moreover, Spark Invest Mngmt Ltd Liability Co has 0.11% invested in Ignyta Inc (NASDAQ:RXDX) for 211,000 shares. Manufacturers Life Insur The owns 22,154 shares or 0% of their US portfolio. Voya Mngmt Llc, a Georgia-based fund reported 14,152 shares. Perceptive Advisors reported 435,260 shares or 0.16% of all its holdings. Tang Management Lc has 3.97M shares for 9.59% of their US portfolio. Artal Group holds 0.08% of its portfolio in Ignyta Inc (NASDAQ:RXDX) for 750,000 shares. Sabby Lc last reported 0.06% of its portfolio in the stock. Citigroup accumulated 20 shares or 0% of the stock. The California-based Blackrock Institutional Tru Na has invested 0% in Ignyta Inc (NASDAQ:RXDX).
Insider Transactions: Since May 4, 2016, the stock had 1 buy, and 0 sales for $1.45 million net activity. The insider Casdin Alexander W. bought 232,000 shares worth $1.45M.
More important recent Ignyta Inc (NASDAQ:RXDX) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on December 06, 2013, also Fool.com published article titled: “Why Ignyta Inc. Shares Are Skyrocketing Higher”, Businesswire.com published: “Ignyta Announces Initiation of STARTRK â€œNext Generationâ€ Phase 1/1b Pediatric …” on December 09, 2015. More interesting news about Ignyta Inc (NASDAQ:RXDX) was released by: Seekingalpha.com and their article: “Ignyta Is Proof That Biotech Bargains Still Exist” with publication date: August 31, 2016.
RXDX Company Profile
Prometheus RxDx Corp., incorporated in June 2009, is a wholly owned subsidiary of Prometheus Laboratories Inc. The Firm is engaged in the development and commercialization of pharmaceutical and diagnostic products that enable physicians to provide individualized patient care. It focuses on the detection, diagnosis and treatment of disorders within the fields of gastroenterology and oncology. It operates in two divisions: the pharmaceutical products segment that markets and sells prescription drugs, and the diagnostic testing services segment, which includes specific immunoassays to detect and differentiate diseases, pharmacogenetic testing and drug metabolite monitoring. The pharmaceutical products for gastrointestinal diseases and disorders includes ENTOCORT EC (budesonide) Capsules, which is indicated for the treatment of mild to moderate active Crohnâ€™s disease involving the ileum and/or the ascending colon, and LOTRONEX (alosetron hydrochloride) Tablets, for use in female patients with severe diarrhea-predominant irritable bowel syndrome (IBS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.